The two-speed year

The headline +72.8% one-year average return for the eight-name bucket (ALNY, ASND, CGON, CYTK, DNLI, DYN, MLTX, PCVX) checks out exactly, but it is not broad-based. CGON (+180.9%), DYN (+178.2%) and CYTK (+116.9%) carry the bucket, while ALNY (-11.2%) and MLTX (-65.7%) are drags. The MLTX number is the biggest correction to the original thesis: the stock did not have a gradual re-rating -- it crashed roughly 90% in a single session on September 29, 2025 after Phase 3 VELA data showed sonelokimab was uncompetitive with Bimzelx in hidradenitis suppurativa, a result that also triggered a securities fraud class action. Alnylam tells a different but equally unflattering story: it rotated from strongly bullish in mid-2025 into strongly bearish for most of Jan-June 2026 and now sits in mildly bearish, the bucket's only bear-band name, after concerning 2026/2030 guidance sent shares down nearly 19% between October 2025 and January 2026.

Why the flat month isn't a rollover

Despite the -1.6% average 30-day return, the intact-trend read holds up: six of eight names (ASND, CGON, CYTK, DNLI, DYN, MLTX) currently sit in strongly bullish bands and PCVX is mildly bullish -- only ALNY is bearish. The flat month is a shallow, broad pullback (seven of eight names down 1.5-9%) almost entirely offset by DYN's +21.8% surge, which itself reflects an abrupt reversal rather than a slow grind: DYN was in a strongly bearish band as recently as June 1 before flipping to strongly bullish by June 23, coinciding with completion of enrollment in Dyne's ACHIEVE registrational trial for DM1, a move Yahoo Finance tied to growing confidence in Dyne's late-stage neuromuscular pipeline. ASND's mildly bullish-to-strongly bullish upgrade on July 2 is confirmed and coincides with an accelerating Yorvipath launch: full-year 2025 revenue of €477M and Q1 2026 revenue of €197M, with patient enrollments climbing from ~5,300 to over 6,300.

The M&A backdrop is real, but sizes matter

The deal environment underpinning this thesis has genuinely strengthened: 24 biopharma deals worth over $64B closed in the first four months of 2026 versus 14 deals worth $24.5B a year earlier, against a backdrop of $230B in revenue facing patent expiry by 2030. But deal structure has shifted toward $1B-$10B bolt-ons rather than mega-mergers, and antitrust regulators have kept the stricter 2023 merger guidelines in place rather than loosening them. That matters because ALNY ($39.9B), ASND ($16.7B) and CYTK ($11.5B) have all grown past the bolt-on sweet spot, even as speculative chatter persists -- Novartis and Amgen interest in Cytokinetics and unresolved takeover rumors around Ascendis. DYN ($2.86B), CGON ($5.9B), DNLI ($2.96B), MLTX ($1.29B) and PCVX ($8.4B) remain squarely in the range pharma is actually buying.

Catalysts still ahead

The binary readouts underpinning the bucket's re-rating haven't fired yet. Cytokinetics launched aficamten commercially in the EU in June 2026 following U.S. and China approvals. Vaxcyte's VAX-31 pivotal trial completed enrollment in March 2026, with topline data due Q4 2026. CG Oncology expects its cretostimogene BLA submission in Q4 2026 and holds cash into 2029, reducing near-term deal urgency for that name specifically. A biotech IPO and financing surge -- the strongest since the COVID era -- supports the broader re-rating thesis, but all eight names still carry deeply negative trailing earnings multiples, meaning the case rests on pipeline execution and takeout optionality rather than current fundamentals.